1

Lymphoma Treatment Market (By Type: Hodgkin Lymphoma (HL), Non-Hodgkin Lymphoma (NHL); By Drug: Adcetris, Rituxan/Mabthera, Imbruvica, Keytruda, Revlimid, Others) - Global Industry Analysis, Market Size, Opportunities And Forecast 2020 - 2027

Category : Healthcare and Pharmaceuticals | Delivery Format: PDF | Status: Published | Pages : 190

CHAPTER 1. Industry Overview of Lymphoma Treatment
1.1. Definition and Scope
1.1.1. Definition of Lymphoma Treatment
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Lymphoma Treatment Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Lymphoma Treatment Market By Type
1.2.3. Lymphoma Treatment Market By Drug
1.2.4. Lymphoma Treatment Market by Regions

CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources

CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restrain 1
3.2.2. Restrain 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Lymphoma Treatment Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Lymphoma Treatment Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Cost Structure Analysis
3.8.1. Price Trend of Key Raw Materials
3.8.2. Raw Material Suppliers
3.8.3. Proportion of Manufacturing Cost Structure
3.8.3.1. Raw Material
3.8.3.2. Labor Cost
3.8.3.3. Manufacturing Expense
3.9. Regulatory Compliance
3.10. Competitive Landscape, 2019
3.10.1. Player Positioning Analysis
3.10.2. Key Strategies Adopted By Leading Players

CHAPTER 4. Lymphoma Treatment Market By Type
4.1. Introduction
4.2. Lymphoma Treatment Revenue By Type
4.2.1. Lymphoma Treatment Revenue (US$ Mn) and Forecast, By Type, 2016-2027
4.2.2. Hodgkin Lymphoma (HL)
4.2.2.1. Hodgkin Lymphoma (HL) Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
4.2.3. Non-Hodgkin Lymphoma (NHL)
4.2.3.1. Non-Hodgkin Lymphoma (NHL) Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027

CHAPTER 5. Lymphoma Treatment Market Revenue By Drug
5.1. Introduction
5.2. Lymphoma Treatment Revenue (US$ Mn) By Drug
5.2.1. Lymphoma Treatment Revenue (US$ Mn) and Forecast By Drug, 2016 - 2027
5.2.2. Adcetris
5.2.2.1. Adcetris Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.3. Rituxan/Mabthera
5.2.3.1. Rituxan/Mabthera Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.4. Imbruvica
5.2.4.1. Imbruvica Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.5. Keytruda
5.2.5.1. Keytruda Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.6. Revlimid
5.2.6.1. Revlimid Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.7. Others
5.2.7.1. Others Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027

CHAPTER 6. North America Lymphoma Treatment Market By Country
6.1. North America Lymphoma Treatment Overview
6.2. U.S.
6.2.1. U.S. Lymphoma Treatment Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
6.2.2. U.S. Lymphoma Treatment Market Revenue (US$ Mn) and Forecast By Drug, 2016-2027
6.3. Canada
6.3.1. Canada Lymphoma Treatment Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
6.3.2. Canada Lymphoma Treatment Market Revenue (US$ Mn) and Forecast By Drug, 2016-2027
6.4. North America PEST Analysis

CHAPTER 7. Europe Lymphoma Treatment Market By Country
7.1. Europe Lymphoma Treatment Market Overview
7.2. U.K.
7.2.1. U.K. Lymphoma Treatment Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
7.2.2. U.K. Lymphoma Treatment Market Revenue (US$ Mn) and Forecast By Drug, 2016-2027
7.3. Germany
7.3.1. Germany Lymphoma Treatment Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
7.3.2. Germany Lymphoma Treatment Market Revenue (US$ Mn) and Forecast By Drug, 2016-2027
7.4. France
7.4.1. France Lymphoma Treatment Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
7.4.2. France Lymphoma Treatment Market Revenue (US$ Mn) and Forecast By Drug, 2016-2027
7.5. Spain
7.5.1. Spain Lymphoma Treatment Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
7.5.2. Spain Lymphoma Treatment Market Revenue (US$ Mn) and Forecast By Drug, 2016-2027
7.6. Rest of Europe
7.6.1. Rest of Europe Lymphoma Treatment Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
7.6.2. Rest of Europe Lymphoma Treatment Market Revenue (US$ Mn) and Forecast By Drug, 2016-2027
7.7. Europe PEST Analysis

CHAPTER 8. Asia Pacific Lymphoma Treatment Market By Country
8.1. Asia Pacific Lymphoma Treatment Market Overview
8.2. China
8.2.1. China Lymphoma Treatment Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
8.2.2. China Lymphoma Treatment Market Revenue (US$ Mn) and Forecast By Drug, 2016 - 2027
8.3. Japan
8.3.1. Japan Lymphoma Treatment Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
8.3.2. Japan Lymphoma Treatment Market Revenue (US$ Mn) and Forecast By Drug, 2016 - 2027
8.4. India
8.4.1. India Lymphoma Treatment Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
8.4.2. India Lymphoma Treatment Market Revenue (US$ Mn) and Forecast By Drug, 2016 - 2027
8.5. Australia
8.5.1. Australia Lymphoma Treatment Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
8.5.2. Australia Lymphoma Treatment Market Revenue (US$ Mn) and Forecast By Drug, 2016 - 2027
8.6. South Korea
8.6.1. South Korea Lymphoma Treatment Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
8.6.2. South Korea Lymphoma Treatment Market Revenue (US$ Mn) and Forecast By Drug, 2016 - 2027
8.7. Rest of Asia-Pacific
8.7.1. Rest of Asia-Pacific Lymphoma Treatment Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
8.7.2. Rest of Asia-Pacific Lymphoma Treatment Market Revenue (US$ Mn) and Forecast By Drug, 2016 - 2027
8.8. Asia Pacific PEST Analysis

CHAPTER 9. Latin America Lymphoma Treatment Market By Country
9.1. Latin America Lymphoma Treatment Market Overview
9.2. Brazil
9.2.1. Brazil Lymphoma Treatment Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
9.2.2. Brazil Lymphoma Treatment Market Revenue (US$ Mn) and Forecast By Drug, 2016 - 2027
9.3. Mexico
9.3.1. Mexico Lymphoma Treatment Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
9.3.2. Mexico Lymphoma Treatment Market Revenue (US$ Mn) and Forecast By Drug, 2016 - 2027
9.4. Rest of Latin America
9.4.1. Rest of Latin America Lymphoma Treatment Market Revenue (US$ Mn) and Forecast By Type, 2016 – 2027
9.4.2. Rest of Latin America Lymphoma Treatment Market Revenue (US$ Mn) and Forecast By Drug, 2016 - 2027

CHAPTER 10. Middle East & Africa Lymphoma Treatment Market By Country
10.1. Middle East & Africa Lymphoma Treatment Market Overview
10.2. Saudi Arabia
10.2.1. Saudi Arabia Lymphoma Treatment Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
10.2.2. Saudi Arabia Lymphoma Treatment Market Revenue (US$ Mn) and Forecast By Drug, 2016 - 2027
10.3. UAE
10.3.1. UAE Lymphoma Treatment Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
10.3.2. UAE Lymphoma Treatment Market Revenue (US$ Mn) and Forecast By Drug, 2016 - 2027
10.4. Rest of Middle East & Africa
10.4.1. Rest of Middle East & Africa Lymphoma Treatment Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
10.4.2. Rest of Middle East & Africa Lymphoma Treatment Market Revenue (US$ Mn) and Forecast By Drug, 2016 - 2027

CHAPTER 11. Player Analysis Of Lymphoma Treatment
11.1. Lymphoma Treatment Market Company Share Analysis
11.2. Competition Matrix
11.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
11.2.2. New Product Launches and Product Enhancements
11.2.3. Mergers And Acquisition In Global Lymphoma Treatment Market
11.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements

CHAPTER 12. COMPANY PROFILE
12.1. Merck Sharp & Dohme Corp.
12.1.1. Company Snapshot
12.1.2. Business Overview
12.1.3. Financial Overview
12.1.3.1. Revenue (US$ Mn), 2019
12.1.3.2. Merck Sharp & Dohme Corp. 2019 Lymphoma Treatment Business Regional Distribution
12.1.4. Product/ Service and Specification
12.1.5. Recent Developments & Business Strategy
12.1.6. Manufacturing Plant Footprint Analysis
12.2. SGS SA
12.3. Toxikon, Inc
12.4. The Intertech group
12.5. Pace Analytical Services, LLC
12.6. Seagen Inc.
12.7. Takeda Pharmaceutical Company
12.8. Johnson & Johnson Services, Inc.
12.9. Lilly.
12.10. Abbott.
12.11. Bristol-Myers Squibb Company
12.12. Celgene Corporation
12.13. F. Hoffmann-La Roche Ltd.
12.14. Others

Cart Summary